News

JERUSALEM--(BUSINESS WIRE)--May. 14, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV. Jon Congleton, Senior Vice President and General Manager, Global CNS will present on Wednesday, May 15, 2013. What:   Teva Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference Read More »

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatmentof agitation associated with schizophrenia and bipolar disorder NORTH WALES, Pa. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--May. 8, 2013-- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) inhalation powder 10 mg for the acute Read More »

JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that Paul J. Sekhri has been appointed Group Executive Vice President, Global Business Development and Chief Strategy Officer. Mr. Sekhri has over 25 years of operational experience in the life sciences industry, including business development, business strategy, general management, drug development, and commercial strategy. In his new role, Mr. Sekhri will oversee Teva’s Strategy and Business Development group, reporting direc Read More »

-- Quartette™ Represents the Next Generation of Extended Regimen Oral Contraceptives -- JERUSALEM--(BUSINESS WIRE)--Mar. 29, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy. Quartette™ represents the next generation of extended regimen oral contraceptives to be approved by the FDA, and was designed to minimize breakthrough bleeding (BTB Read More »

Data presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) showed early treatment with laquinimod demonstrated significant benefit in terms of slowing disability progression compared to delayed treatment 36-month data affirmed the safety profile demonstrated in the ALLEGRO pivotal clinical trial Additional animal preclinical data demonstrated laquinimod restored myelination in the brain and spinal cord JERUSALEM & LUND, Sweden--(BUSIN Read More »

Results Add to Evidence for Azilect as an Effective and Well-Tolerated Treatment Option at Different Stages of the Progression of Parkinson’s Disease (PD) JERUSALEM--(BUSINESS WIRE)--Mar. 20, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and H. Lundbeck A/S announced today that a double-blind, placebo controlled, randomized, multicenter study of Azilect® (rasagiline tablets) met its primary endpoint. The study, known as ANDANTE (Add oN to Dopamine AgoNists in the TrEatment of Parkinson’s disease), assessed the Read More »

JERUSALEM--(BUSINESS WIRE)--Mar. 8, 2013-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete aud Read More »

JERUSALEM--(BUSINESS WIRE)--Mar. 1, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance Company, LLC has called for redemption its approximately $500 million outstanding principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3). The redemption is being funded with cash on hand. The redemption date will be March 22, 2013, and the redemption price will equal the principal amount of the notes plus a make whole premium calculated in accordanc Read More »

JERUSALEM--(BUSINESS WIRE)--Feb. 25, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 2013 RBC Capital Markets Global Healthcare Conference. Jon Congleton, SVP, Global Medicines Group, will present on Wednesday, February 27, 2013. What:   Teva Presentation at the 2013 RBC Capital Markets Global Healthcare Conference Read More »

Data to be Presented Regarding Impact on Sleep Quality and Nasal Symptom Relief at 24 Hours Post Dose in Patients with Seasonal and Perennial Allergic Rhinitis JERUSALEM--(BUSINESS WIRE)--Feb. 22, 2013-- Teva Pharmaceutical Industries Ltd. announced today that additional data analyzed from the Phase III clinical program for QNASL® (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, Texas on February 22-26, 201 Read More »